Irritable Bowel Syndrome and Risk of Parkinson's Disease in Finland: A Nationwide Registry-Based Cohort Study.


Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
2021
Historique:
pubmed: 2 3 2021
medline: 15 12 2021
entrez: 1 3 2021
Statut: ppublish

Résumé

The gastrointestinal tract is considered as a potential origin of Parkinson's disease (PD) pathology. Besides constipation, appendectomy and inflammatory bowel disease have also been associated with a higher PD-risk, but findings have been inconsistent. To date, there is only one previous study suggesting that irritable bowel syndrome (IBS) is associated with an increased risk of PD. To evaluate whether IBS is associated with a higher risk of PD. In this retrospective registry-based cohort study, we identified 28,150 patients that were diagnosed with IBS (IBS+) during the years 1998-2014, using data from the Finnish Care Register for Health Care. In addition, 98,789 IBS-free reference subjects (IBS-) of same age and gender and living in the same municipality were included. The study subjects were followed until the end of the year 2014 to analyze the incidence of PD. The association between IBS and PD was assessed by a Cox proportional hazards model. Diagnosis of IBS was associated with a higher hazard of PD with an adjusted hazard ratio (aHR) of 1.70 (95% CI 1.27-2.26). However, the ratio of hazard rates for PD between IBS+ and IBS- subjects was not constant over time. The Cox model with time-varying coefficient for IBS status showed that the hazard of PD was significantly higher in IBS patients only during the first two years of follow-up (aHR 2.96, 95% CI 1.78-4.92). Our findings indicate that the association between IBS and PD is likely explained by reverse causation and detection bias. It remains open whether IBS is an actual risk factor or a prodromal symptom of PD.

Sections du résumé

BACKGROUND
The gastrointestinal tract is considered as a potential origin of Parkinson's disease (PD) pathology. Besides constipation, appendectomy and inflammatory bowel disease have also been associated with a higher PD-risk, but findings have been inconsistent. To date, there is only one previous study suggesting that irritable bowel syndrome (IBS) is associated with an increased risk of PD.
OBJECTIVE
To evaluate whether IBS is associated with a higher risk of PD.
METHODS
In this retrospective registry-based cohort study, we identified 28,150 patients that were diagnosed with IBS (IBS+) during the years 1998-2014, using data from the Finnish Care Register for Health Care. In addition, 98,789 IBS-free reference subjects (IBS-) of same age and gender and living in the same municipality were included. The study subjects were followed until the end of the year 2014 to analyze the incidence of PD. The association between IBS and PD was assessed by a Cox proportional hazards model.
RESULTS
Diagnosis of IBS was associated with a higher hazard of PD with an adjusted hazard ratio (aHR) of 1.70 (95% CI 1.27-2.26). However, the ratio of hazard rates for PD between IBS+ and IBS- subjects was not constant over time. The Cox model with time-varying coefficient for IBS status showed that the hazard of PD was significantly higher in IBS patients only during the first two years of follow-up (aHR 2.96, 95% CI 1.78-4.92).
CONCLUSION
Our findings indicate that the association between IBS and PD is likely explained by reverse causation and detection bias. It remains open whether IBS is an actual risk factor or a prodromal symptom of PD.

Identifiants

pubmed: 33646176
pii: JPD202330
doi: 10.3233/JPD-202330
pmc: PMC8150653
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

641-651

Références

Gut. 2019 Jan;68(1):18-24
pubmed: 29785965
Gut. 2019 Jan;68(1):175-176
pubmed: 30021791
World J Gastroenterol. 2014 Sep 14;20(34):12144-60
pubmed: 25232249
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Parkinsonism Relat Disord. 2018 May;50:23-28
pubmed: 29459115
Lancet Neurol. 2015 Jun;14(6):625-39
pubmed: 25987282
Gastroenterology. 2006 Apr;130(5):1480-91
pubmed: 16678561
Neurology. 2009 Nov 24;73(21):1752-8
pubmed: 19933976
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
EBioMedicine. 2019 Jun;44:691-707
pubmed: 31221587
Aging Clin Exp Res. 2020 Nov;32(11):2201-2209
pubmed: 31538320
Stat Med. 2013 Nov 30;32(27):4696-708
pubmed: 23761197
J Parkinsons Dis. 2017;7(s1):S71-S85
pubmed: 28282810
Mov Disord. 2012 May;27(6):716-9
pubmed: 22550057
Mov Disord. 2020 Mar;35(3):431-442
pubmed: 31737957
Nat Rev Neurosci. 2017 Jul;18(7):435-450
pubmed: 28592904
BMJ. 2014 May 02;348:g2979
pubmed: 25134102
JAMA Neurol. 2018 Aug 1;75(8):939-946
pubmed: 29710331
World J Gastroenterol. 2012 Oct 7;18(37):5151-63
pubmed: 23066308
PLoS One. 2018 Nov 20;13(11):e0207729
pubmed: 30458031
Eur J Neurol. 2017 Nov;24(11):1375-1383
pubmed: 28891262
J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):710-6
pubmed: 26345189
J Parkinsons Dis. 2018;8(1):1-12
pubmed: 29154293
Aliment Pharmacol Ther. 2004 Aug 1;20(3):339-45
pubmed: 15274671
Eur J Epidemiol. 2014 Jan;29(1):57-62
pubmed: 24442494
PLoS One. 2016 Apr 07;11(4):e0151841
pubmed: 27055126
Inflamm Bowel Dis. 2019 Jan 1;25(1):111-123
pubmed: 29788069
Neuropathol Appl Neurobiol. 2007 Dec;33(6):599-614
pubmed: 17961138
Neurology. 2009 Feb 3;72(5):432-8
pubmed: 19188574
Parkinsonism Relat Disord. 2016 Jul;28:18-22
pubmed: 27234704
BMC Med Res Methodol. 2008 Oct 30;8:70
pubmed: 18973665
Ann Neurol. 2015 Oct;78(4):522-9
pubmed: 26031848
Eur Arch Psychiatry Clin Neurosci. 2014 Dec;264(8):651-60
pubmed: 24705634
Mov Disord. 2015 Mar;30(3):350-8
pubmed: 25476529
Eur J Neurol. 2008 Apr;15 Suppl 1:14-20
pubmed: 18353132
Scand J Public Health. 2012 Aug;40(6):505-15
pubmed: 22899561
Ann Epidemiol. 2014 Mar;24(3):206-13
pubmed: 24462274
Arch Neurol. 2010 Jul;67(7):798-801
pubmed: 20625084
Gastroenterology. 2016 Feb 19;:
pubmed: 27144617
JAMA. 2020 Apr 14;323(14):1401-1402
pubmed: 32167523
Nat Rev Neurol. 2015 Nov;11(11):625-36
pubmed: 26503923
Sci Rep. 2017 Aug 14;7(1):8073
pubmed: 28808281
PLoS One. 2011;6(12):e28032
pubmed: 22145021

Auteurs

Tuomas H Mertsalmi (TH)

Department of Neurology, Helsinki University Hospital and Department of Clinical Neurosciences (Neurology), University of Helsinki, Helsinki, Finland.

Anna But (A)

Biostatistics consulting, Department of Public Health, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Eero Pekkonen (E)

Department of Neurology, Helsinki University Hospital and Department of Clinical Neurosciences (Neurology), University of Helsinki, Helsinki, Finland.

Filip Scheperjans (F)

Department of Neurology, Helsinki University Hospital and Department of Clinical Neurosciences (Neurology), University of Helsinki, Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH